Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Bipolar I Disorder

Bipolar I Disorder

Part of Bipolar Disorder

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Bipolar I Disorder

42 trials tracked for Bipolar I Disorder: 26 in phase 3 or 4 and 11 with published results. The most-cited published study has 134 citations.

42Trials tracked
26Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 4 Phase 3 22 Phase 2 11 Phase 1 2 Other / NA 3
  1. Phase 3 Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients Completed · 134 cited
  2. Phase 3 Safety and Efficacy of Cariprazine for Bipolar I Disorder Completed · 121 cited
  3. Phase 3 Sensoril(Ashwaganhda)for Bipolar Disorder Completed · 120 cited
  4. Phase 4 Sequential Multiple Assignment Treatment for Bipolar Disorder Completed · 39 cited
  5. Phase 3 Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder Completed · 36 cited
  6. Phase 4 The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. Completed · 20 cited
Show 36 more trials
  1. Phase 3 Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder Completed · 16 cited
  2. Phase 3 Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder Completed · 11 cited
  3. Phase 3 A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. Completed · 10 cited
  4. Phase 3 Staccato Loxapine in Agitated Patients With Bipolar Disorder Completed · 10 cited
  5. Phase 3 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Completed · 7 cited
  6. Phase 4 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients Completed
  7. Phase 4 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed
  8. Phase 3 Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex Completed
  9. Phase 3 This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 Completed
  10. Phase 3 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder Completed
  11. Phase 3 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Completed
  12. Phase 3 A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. Completed
  13. Phase 3 A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features Completed
  14. Phase 3 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed
  15. Phase 3 Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed Completed
  16. Phase 3 A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed
  17. Phase 3 A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed
  18. Phase 3 Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder Completed
  19. Phase 3 Risperdal Consta for Bipolar Disorder Completed
  20. Phase 3 A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed
  21. Phase 2 Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain Completed
  22. Phase 2 Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder Completed
  23. Phase 2 Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents Completed
  24. Phase 2 Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders Completed
  25. Phase 2 A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode Completed
  26. Phase 2 Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder Completed
  27. Phase 2 Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder Completed
  28. Phase 2 Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System Completed
  29. Phase 2 A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder Completed
  30. Phase 2 Gabapentin for Bipolar & Cannabis Use Disorders Completed
  31. Phase 2 Treating Smokers With Mental Illness Completed
  32. Phase 1 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1) Completed
  33. Phase 1 A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020) Completed
  34. N/A iTBS in Bipolar I Depression Completed
  35. N/A Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study Completed
  36. N/A A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion Completed

Showing the 42 most-cited and recently-updated of 42 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Bipolar I Disorder: what the trials found

Several antipsychotic agents have demonstrated efficacy in managing manic symptoms for Bipolar I Disorder. Cariprazine showed significant reductions in Young Mania Rating Scale (YMRS) scores at week 3 6 and week 16 8, as well as improvements in Clinical Global Impression-Severity (CGI-S) scores 6. Olanzapine was associated with significant reductions in YMRS scores [3, 4] and HAMD scores 4. Brexpiprazole demonstrated changes in YMRS scores at week 3 [16, 17], while Lurasidone showed a reduction of -1.0 in YMRS total score by week 12 18.

Long-term management and maintenance are supported by various formulations. IM Depot Aripiprazole significantly extended the time to recurrence of any mood episode compared to placebo 5 and improved CGI-BP-S (Mania) scores 5. Oral Aripiprazole also showed a reduction in CGI-BP severity for mania 21. Staccato Loxapine demonstrated significant improvements in Clinical Global Impression-Improvement (CGI-I) scores and reductions in the PANSS Excited Component (PEC) score after a single dose compared to placebo 11.

Weight gain is a noted outcome in some trials; for example, ALKS 3831 was associated with significant increases in body weight at week 12 9. Olanzapine was evaluated regarding BMI changes over 52 weeks, which did not reach statistical significance 3.

Recent results — preliminary, needs further review

  • Ketamine Hydrochloride was evaluated in a Phase 4 trial for Bipolar I Disorder 2.

For the clinician treating this condition

  • Cariprazine and Olanzapine are supported by evidence for reducing manic symptoms as measured by YMRS scores [3, 4, 6, 8].
  • IM Depot Aripiprazole and oral Aripiprazole provide established options for managing mania and preventing mood episode recurrence [5, 21].
  • Staccato Loxapine showed rapid improvement in clinical global impression and excited components after a single dose 11.

AI synthesis of 10 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Unipolar mania prevalence in patients with bipolar type I disorder is 21.1%
Psychiatry Meta-analysis
Unipolar mania prevalence in patients with bipolar type I disorder is 21.1% About one in five people with bipolar disorder experience mania
This meta-analysis of 35 independent samples indicates a pooled prevalence of unipolar mania (UM) in adults with bipolar type I disorder of …
New data shows that over 20% of adults with bipolar type I disorder experience unipolar mania, highlighting a need for better clinical aware…
Jul 18, 2026
FDA Approves Lamotrigine Tablets (lamotrigine) for Epilepsy and Bipolar Disorder Maintenance
Neurology FDA Approval
FDA Approves Lamotrigine Tablets (lamotrigine) for Epilepsy and Bipolar Disorder Maintenance The FDA has approved a drug called lamotrigine for epilepsy and bipolar disorder treatment
Lamotrigine tablets were approved as adjunctive therapy for partial-onset seizures, PGTC seizures, and Lennox-Gastaut syndrome in patients a…
The FDA has approved lamotrigine to help control seizures in children as young as two and maintain mood stability for adults with bipolar di…
FDA Apr 14, 2026
FDA Approves Lamotrigine for Adjunctive Therapy in Epilepsy and Maintenance in Bipolar I Disorder
Neurology FDA Approval
FDA Approves Lamotrigine for Adjunctive Therapy in Epilepsy and Maintenance in Bipolar I Disorder FDA approves lamotrigine, a medicine for epilepsy and bipolar disorder
Lamotrigine is approved for adjunctive therapy of partial-onset seizures, PGTC seizures, and seizures of Lennox-Gastaut syndrome in patients…
The FDA officially approves lamotrigine for epilepsy and bipolar disorder, confirming a long-used treatment option for adults and children a…
FDA Apr 2, 2026

Research across Bipolar Disorder

Related studies from across the Bipolar Disorder family.

Prenatal exposure to certain psychotropic medications is associated with increased risk of gestational diabetes
Diabetes & Endocrinology Meta-analysis
Prenatal exposure to certain psychotropic medications is associated with increased risk of gestational diabetes Prenatal exposure to certain psychiatric drugs linked to gestational diabetes
This meta-analysis examined the relationship between prenatal exposure to antipsychotics and antidepressants and the risk of gestational dia…
New data shows that some medications used for mental health during pregnancy may increase the risk of gestational diabetes.
Oct 26, 2026
Voice and speech biomarkers show clinical interpretability but lack evidence for validity and deployability
Psychiatry Sys. Review
Voice and speech biomarkers show clinical interpretability but lack evidence for validity and deployability Voice and Speech Patterns May Signal Mental Health Conditions
This scoping review of 68 studies examined voice and speech as digital biomarkers for depression, anxiety, and bipolar disorder. While speci…
New research identifies specific speech patterns, such as slower talking and longer pauses, that may serve as digital markers for depression…
Frontiers Oct 7, 2026
Resting-state functional MRI reveals distinct regional homogeneity patterns in MDD, BD, and Schizophrenia
Psychiatry Meta-analysis
Resting-state functional MRI reveals distinct regional homogeneity patterns in MDD, BD, and Schizophrenia Brain Imaging Reveals Shared Patterns in Depression and Schizophrenia
This meta-analysis of resting-state functional MRI studies identifies specific regional homogeneity (ReHo) abnormalities in patients with MD…
New research identifies specific brain activity patterns that overlap and differ between depression, bipolar disorder, and schizophrenia.
Oct 1, 2026
Bipolar disorder is associated with increased cerebrospinal fluid and intracranial volumes compared to controls
Psychiatry Meta-analysis
Bipolar disorder is associated with increased cerebrospinal fluid and intracranial volumes compared to controls Brain structure differences found in people with bipolar disorder
This meta-analysis of adult patients with Bipolar Disorder identifies significant increases in cerebrospinal fluid (CSF) volume, intracrania…
New research shows specific differences in brain fluid and volume in people with bipolar disorder compared to those without the condition.
Oct 1, 2026
Ketamine modulates NMDA receptors and glutamate transmission for treatment-resistant depression and other psychiatric disorders
Psychiatry Meta-analysis
Ketamine modulates NMDA receptors and glutamate transmission for treatment-resistant depression and other psychiatric disorders Ketamine Shows Potential for Treatment-Resistant Depression and Anxiety
This systematic review synthesizes the pharmacology, network-level effects, and clinical applications of ketamine for conditions including t…
Ketamine may offer new pathways for treating treatment-resistant depression, PTSD, and anxiety by altering brain circuits and signaling.
Frontiers Oct 1, 2026
Lifestyle Therapy Matches CBT for Moderate-to-Severe Depression in Australian Trial
Psychiatry RCT
Lifestyle Therapy Matches CBT for Moderate-to-Severe Depression in Australian Trial Lifestyle Therapy Shows Similar Results to CBT for Depression
A telehealth lifestyle program was non-inferior to CBT for depressive symptoms at 8 weeks, with MADRS drops of 8.55 versus 6.82 points.
A new trial shows that a lifestyle program involving diet and exercise is as effective as cognitive behavioral therapy for moderate to sever…
medRxiv Sep 11, 2026
Barriers to mental health care for Black populations include racism, stigma, and socioeconomic determinants
Psychiatry Sys. Review
Barriers to mental health care for Black populations include racism, stigma, and socioeconomic determinants Barriers to mental health care for Black patients identified
This scoping review of 254 sources identifies prevalent mental health disorders and systemic barriers affecting the Black population. Key fi…
New research highlights how racism, stigma, and lack of access create significant hurdles for Black people seeking mental health care.
Frontiers Sep 5, 2026
Increased Risk of Dementia Diagnosis Among Individuals Diagnosed With Bipolar Disorder
Psychiatry Meta-analysis
Increased Risk of Dementia Diagnosis Among Individuals Diagnosed With Bipolar Disorder Bipolar disorder linked to triple dementia risk
A large-scale meta-analysis identifies a significant correlation between bipolar disorder and an elevated risk of dementia diagnosis.
People with bipolar disorder face a higher risk of dementia, a new analysis finds. The link is strong but the evidence has limits.
Sep 1, 2026
253 autism-associated genes identified via rare coding variation in 62,429 individuals
Genetics & Precision Medicine Meta-analysis
253 autism-associated genes identified via rare coding variation in 62,429 individuals 253 genes linked to autism may also affect other conditions
This meta-analysis of exome sequencing data from over 1.5 million individuals identified 253 autism-associated genes and 497 genes impacting…
A massive genetic study found 253 autism-linked genes, many tied to other brain and body conditions, opening new paths for understanding.
medRxiv Aug 30, 2026
Combined sleep and circadian interventions improve depressive symptoms and sleep quality in adults with mental disorders
Psychiatry Meta-analysis
Combined sleep and circadian interventions improve depressive symptoms and sleep quality in adults with mental disorders Sleep and Circadian Interventions May Ease Depressive Symptoms
This systematic review and meta-analysis of randomized trials indicates that combined sleep and circadian interventions significantly reduce…
Targeting sleep and circadian rhythms may improve mood, sleep quality, and daily functioning for adults living with depression and other men…
Frontiers Aug 9, 2026
Specific clinical presentations and demographic factors contribute to delayed diagnosis of bipolar disorder
Psychiatry Sys. Review
Specific clinical presentations and demographic factors contribute to delayed diagnosis of bipolar disorder Factors linked to late diagnosis in bipolar disorder patients
This narrative synthesis of 49 studies identifies complex precursors for delayed bipolar disorder diagnosis, including history of depression…
Identifying why people with bipolar disorder often wait years for a correct diagnosis can help doctors provide faster, more effective care.
medRxiv Aug 9, 2026
818 consensus loci identify distinct neurodevelopmental, synaptic, and metabolic pathways in schizophrenia and bipolar disorder
Genetics & Precision Medicine Meta-analysis
818 consensus loci identify distinct neurodevelopmental, synaptic, and metabolic pathways in schizophrenia and bipolar disorder Genetic map reveals why schizophrenia and bipolar disorder affect thinking differently
This meta-analysis identifies 818 consensus genetic loci associated with cognitive divergence in schizophrenia and bipolar disorder. The stu…
New genetic map reveals 818 loci linked to schizophrenia and bipolar disorder, showing why thinking skills vary. Some genes raise risk but b…
medRxiv Aug 6, 2026